Welcome to our dedicated page for Burning Rock Biotech American Depositary Shares news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech American Depositary Shares stock.
Burning Rock Biotech Limited (NASDAQ: BNR, LSE: BNR) is a pioneering cancer diagnostics company headquartered in China, established in 2014. The company is dedicated to leveraging next-generation sequencing (NGS) technology to advance precision oncology. This innovative approach aids in the selection of cancer therapies and the early detection of cancer, enhancing treatment outcomes and patient care.
Burning Rock operates through three primary segments: Central laboratory business, In-hospital business, and Pharma research and development services. The central laboratory business generates the majority of the company’s revenue. The company’s suite of products includes Pan-HEME, OncoScreen-WES, brPROPHET, and OncoScreen Plus, which provide comprehensive cancer profiling and support personalized treatment plans.
In a strategic move to comply with NASDAQ Listing Rules 5810(c)(3)(A), Burning Rock must meet the minimum bid price requirement by June 26, 2024. Should the company's ADSs maintain a closing bid price of at least US$1.00 for ten consecutive business days, NASDAQ will confirm compliance, closing the matter. Failing this, the company might be granted an additional 180-day period to meet the requirement.
Recently, Burning Rock announced an ADS Ratio Change, equivalent to a one-for-ten reverse ADS split, effective immediately. Certificate holders must surrender existing ADSs for the new ratio, while uncertificated ADSs will auto-adjust. This change is expected to proportionally increase the ADS price, although no guarantees are provided.
Burning Rock’s mission, “Guard Life via Science,” underscores its commitment to advancing cancer diagnostics and treatment through scientific innovation. The company continues to make significant strides in cancer early detection, moving beyond proof-of-concept R&D into clinical validation.
For more information, visit ir.brbiotech.com.
Burning Rock Biotech Limited (NASDAQ: BNR) announced a collaboration with IMPACT Therapeutics to provide testing services for the ATR inhibitor IMP9064, which has received IND clearance from the FDA for a Phase I/II clinical study in the U.S. The collaboration leverages Burning Rock's CLIA-certified labs in Guangzhou, China and California. IMP9064 shows high potency against ATR, suggesting a promising therapeutic window, especially in combination with Senaparib. This partnership supports Burning Rock's expansion in precision oncology and strengthens its capabilities in companion diagnostics.
Burning Rock Biotech Limited (NASDAQ: BNR) announced its plans to release unaudited financial results for Q3 2021 on November 16, 2021, prior to U.S. market opening. The company will hold a conference call at 8:00 a.m. ET to discuss the results. Burning Rock specializes in next generation sequencing (NGS) technology for precision oncology, claiming a leading market share in China with over 273,000 tests completed. Investors can access the earnings release via their investor relations website.
Burning Rock Biotech (NASDAQ: BNR) reported Q2 2021 revenues of RMB127.3 million (US$19.7 million), a 19.0% increase year-over-year. The company is focused on early cancer detection technology and plans to commercialize its 6-cancer early detection product in 2022, with contracts signing at six hospitals underway. However, operating expenses surged 93% to RMB292.3 million (US$45.3 million), leading to a net loss of RMB203.7 million (US$31.5 million). The company adjusted its 2021 revenue guidance to approximately RMB500 million, reflecting challenges from COVID-related testing impacts.
Burning Rock Biotech Limited (NASDAQ: BNR) has partnered with IMPACT Therapeutics to advance companion diagnostics (CDx) for the PARP inhibitor Senaparib, targeting prostate cancer. The partnership aims for global CDx submissions to the FDA and NMPA, leveraging Burning Rock's accredited labs in China and California. Senaparib is currently undergoing multiple clinical trials, including a Phase III trial for metastatic castration-resistant prostate cancer (mCRPC). This collaboration is expected to expedite clinical research, benefiting patients worldwide.
Burning Rock Biotech Limited (NASDAQ: BNR) will release its unaudited financial results for Q2 2021 on August 31, 2021, before the U.S. market opens. A conference call will follow at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, having completed over 273,000 tests. Burning Rock's focus includes NGS-based therapy selection and cancer early detection, which is in the clinical validation stage. Investors can access earnings results on their investor relations website.
Burning Rock Biotech (NASDAQ: BNR) reported Q1 2021 revenues of RMB106.6 million (US$16.3 million), up 58.4% from Q1 2020, but down 19.1% sequentially due to COVID-19 and seasonal impacts. Their central laboratory revenue rose 61.6% to RMB74.6 million (US$11.4 million), driven by a 64.9% increase in patient tests. However, net loss expanded to RMB171.4 million (US$26.2 million) from RMB52.6 million in Q1 2020. The company forecasts 2021 revenues at approximately RMB610 million (US$93.1 million), indicating 41.9% growth from 2020.
Burning Rock Biotech Limited (NASDAQ: BNR) has launched the PRESCIENT study, the first blood-based pan-cancer early-detection initiative in China using a multi-omics approach. This groundbreaking study will enroll 11,879 participants across 22 cancer types. The project aims to enhance the efficiency of cancer detection through liquid biopsy, promising improved patient outcomes. The study is backed by prominent experts from the National Cancer Center, who emphasize the necessity of advancing early detection technology in China to address rising cancer incidence and to provide clinical evidence for effective diagnostic tools.
Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021. This recognition positions Burning Rock as the only NGS-based precision oncology company from China included in the current MSCI semi-annual index review. The company's mission emphasizes the use of next generation sequencing technology to enhance precision oncology, with significant activities in therapy selection testing and cancer early detection.
Burning Rock Biotech Limited (NASDAQ: BNR) announced a partnership with Abbisko Therapeutics to develop a companion diagnostic (CDx) assay for ABSK091, aimed at detecting FGFR genetic alterations in urothelial carcinoma patients. Prior studies indicated that ABSK091, an FGFR inhibitor, exhibited safety and preliminary efficacy. Abbisko has received IND approval for ABSK091 from the NMPA and plans to initiate phase Ib/II clinical trials in China. This collaboration aims to leverage next-generation sequencing technology to enhance oncology drug development.
Burning Rock Biotech Limited (NASDAQ: BNR) is set to release its unaudited financial results for Q1 2021 on May 25, 2021, before U.S. market opens. The company will hold a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) the same day to discuss these results. Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, leading the market in China with over 273,000 completed tests. More details will be available on their investor relations website.
FAQ
What is the current stock price of Burning Rock Biotech American Depositary Shares (BNR)?
What is the market cap of Burning Rock Biotech American Depositary Shares (BNR)?
What is Burning Rock Biotech Limited?
What are the main business segments of Burning Rock?
How does Burning Rock generate most of its revenue?
What recent compliance measure did Burning Rock announce?
What is the ADS Ratio Change for Burning Rock?
What products does Burning Rock offer?
What is the mission of Burning Rock Biotech Limited?
Where can I find more information about Burning Rock?
What does the ADS ratio change mean for investors?
Are there any changes to Burning Rock's Class A ordinary shares?
